After the experimental treatment for Alzheimer’s named aducanumab failed a futility test, its producers Biogen and Eisai lost hope the Food and Drug Administration would ever approve it. Despite promising clinical results through the approval process, the producers abandoned their project in 2019.  Eight months later, Biogen developed an expanded dataset to reassess aducanumab’s impact...
Read More »

In late March, California became the first state to issue mandatory “shelter in place” orders. By mid-April, nearly 94 percent of the U.S. population was under order to stay at home. Nearly three months later, millions are still desperate to get back to their lives. Protest rallies held to “reopen the economy” have emerged...
Read More »

President Trump recently announced he is extending social distancing guidelines to April 30th. He initially hoped to lift them by Easter. This is far from the first time he has changed his mind on how to best handle the coronavirus pandemic. Although frustrating, the President’s indecisiveness is understandable. The United States recently surpassed China...
Read More »

In 2015, Turning Pharmaceuticals CEO Martin Shkreli increased the price of the drug Daraprim nearly 5,000 percent from $13.50 to $750 per pill. The price hike generated widespread outrage, earning Shkreli the moniker “Pharma Boy” and the designation, “pharmaceutical greed villain.” Daraprim became “the poster child for the issue of high drug prices.”

We’re only a few weeks into the new year, and the Food and Drug Administration will soon make a decision that will affect pharmaceutical regulation for decades. Last year, after failing an FDA-required futility test, Biogen abandoned its efforts to develop an Alzheimer’s treatment named aducanumab. However, after conducting an analysis using an expanded...
Read More »